title: Inhibition of migrating lens epithelial cells by blocking the adhesion molecule integrin: a preliminary report.
abstract: OBJECTIVE
  To evaluate the preventive effect of blocking integrins by sustained release of RGD peptide (arginine-glycin-aspartic acid sequence) or a combination of RGD peptide and ethylenediaminotetraacetic acid (EDTA) on lens epithelial cell (LEC) migration.
  
  
  METHODS
  Nishi Eye Hospital, Jinshikai Medical Foundation, Osaka, Japan.
  
  
  METHODS
  A polylactic-glycolic acid disk containing 4% RGD or a combination of 23% EDTA and 10% RGD was implanted in the capsular bag in five rabbit eyes following standard cataract surgery. The release rate in vitro was 4.4 microg/h for RGD peptide alone and 7.8 and 7.6 microg/h for combined EDTA and RGD peptide, respectively. The contralateral eye received a disk without agents as a control.
  
  
  RESULTS
  After 1 month, a slight inhibition of LEC migration onto the posterior capsule was observed histopathologically in eyes receiving RGD peptide. A significant inhibition was observed in eyes with combined EDTA and RGD.
  
  
  CONCLUSIONS
  Application of RGD peptide and EDTA and RGD peptide may inhibit LEC migration by inhibiting the integrins expressed on the LECs. Blocking adhesion molecules expressed on LECs may reduce posterior capsule opacification.
authors.affiliation: Nishi Eye Hospital, Osaka, Japan.
authors.forename: O
authors.initials: O
authors.lastname: Nishi
authors.forename: K
authors.initials: K
authors.lastname: Nishi
authors.forename: C
authors.initials: C
authors.lastname: Mano
authors.forename: M
authors.initials: M
authors.lastname: Ichihara
authors.forename: T
authors.initials: T
authors.lastname: Honda
authors.forename: I
authors.initials: I
authors.lastname: Saitoh
mesh_terms: D000818:Animals; D001672:Biocompatible Materials; D002386:Cataract / Q000517:prevention & control; D002448:Cell Adhesion / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects* / Q000502:physiology; D002614:Chelating Agents / Q000008:administration & dosage / Q000494:pharmacology*; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination; D004492:Edetic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D004848:Epithelium / Q000187:drug effects / Q000502:physiology; D005500:Follow-Up Studies; D016023:Integrins / Q000037:antagonists & inhibitors*; D019344:Lactic Acid; D007903:Lens Capsule, Crystalline / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D007908:Lens, Crystalline / Q000166:cytology / Q000187:drug effects* / Q000473:pathology; D009842:Oligopeptides / Q000008:administration & dosage / Q000494:pharmacology*; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers; D011817:Rabbits
chemical_list: D001672:Biocompatible Materials; D002614:Chelating Agents; D003692:Delayed-Action Preparations; D016023:Integrins; D009842:Oligopeptides; D011108:Polymers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; C047981:arginyl-glycyl-aspartic acid; D004492:Edetic Acid